Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-9539 in Multiple Myeloma
NCT06484777Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-9539 in multiple myeloma (MM), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Recommended Phase 2 Dose at 24 months. Started Aug 2024; status: recruiting.
02
Drugs
SHR-9539
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06484777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484777.